EP1545572A4 - Conjugates activated by cell surface proteases and therapeutic uses thereof - Google Patents

Conjugates activated by cell surface proteases and therapeutic uses thereof

Info

Publication number
EP1545572A4
EP1545572A4 EP02739474A EP02739474A EP1545572A4 EP 1545572 A4 EP1545572 A4 EP 1545572A4 EP 02739474 A EP02739474 A EP 02739474A EP 02739474 A EP02739474 A EP 02739474A EP 1545572 A4 EP1545572 A4 EP 1545572A4
Authority
EP
European Patent Office
Prior art keywords
cell surface
therapeutic uses
surface proteases
conjugates
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739474A
Other languages
German (de)
French (fr)
Other versions
EP1545572A2 (en
Inventor
Edwin L Madison
Joseph Edward Semple
George P Vlasuk
Scott Jeffrey Kemp
Mallareddy Komandla
Daniel Vanna Siev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Corp
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Publication of EP1545572A2 publication Critical patent/EP1545572A2/en
Publication of EP1545572A4 publication Critical patent/EP1545572A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP02739474A 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof Withdrawn EP1545572A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29326701P 2001-05-23 2001-05-23
US293267P 2001-05-23
PCT/US2002/016819 WO2002095007A2 (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
EP1545572A2 EP1545572A2 (en) 2005-06-29
EP1545572A4 true EP1545572A4 (en) 2006-04-12

Family

ID=23128397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739474A Withdrawn EP1545572A4 (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof

Country Status (5)

Country Link
EP (1) EP1545572A4 (en)
JP (1) JP2005518332A (en)
KR (1) KR20040004642A (en)
CA (1) CA2447023A1 (en)
WO (1) WO2002095007A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
AU2003252734A1 (en) * 2002-07-31 2004-02-16 Yamanouchi Pharmaceutical Co., Ltd. Novel serine protease
CA2535265C (en) 2003-08-22 2014-01-28 Dendreon Corporation Compositions and methods for the treatment of disease associated with trp-p8 expression
JP2008522632A (en) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in the process of bone remodeling
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
HUE029650T2 (en) 2006-02-15 2017-02-28 Dendreon Pharmaceuticals Inc Small-Molecule modulators of TRP-P8 activity
US7772266B2 (en) 2006-02-15 2010-08-10 Dendreon Corporation Small-molecule modulators of TRP-P8 activity
KR100906145B1 (en) * 2006-05-30 2009-07-03 한국생명공학연구원 A anticancer drug comprising inhibitor of TMPRSS4
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
FR2906724B1 (en) 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
TWI465247B (en) 2008-04-11 2014-12-21 Catalyst Biosciences Inc Factor vii polypeptides that are modified and uses thereof
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system
EP2608251A4 (en) 2010-08-18 2014-01-15 Nat Inst Of Advanced Ind Scien Method of manufacturing organic semiconductor thin film and monocrystalline organic semiconductor thin film
EP2814807A4 (en) 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Linear peptide antibiotics
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
BR112015001628A2 (en) 2012-07-25 2017-11-07 Catalyst Biosciences Inc modified factor x polypeptides and their use
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
CA3026074A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. N-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide compounds and their use to treat neurodegenerative diseases
CN111107870A (en) 2017-06-22 2020-05-05 催化剂生物科学公司 Modified membrane serine protease 1(MTSP-1) polypeptides and methods of use thereof
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3932935A1 (en) * 2020-06-29 2022-01-05 Centre National de la Recherche Scientifique Antibacterial peptides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036604A2 (en) * 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
WO2001068145A2 (en) * 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
WO2003104394A2 (en) * 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1161266A4 (en) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, a serine protease and its applications
US20030180804A1 (en) * 2001-10-29 2003-09-25 Corvas International, Inc Solid phase synthesis of chemical libraries

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036604A2 (en) * 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
WO2001068145A2 (en) * 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
WO2003104394A2 (en) * 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARSKY V M ET AL: "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.", JOURNAL OF MEDICINAL CHEMISTRY. 22 NOV 2001, vol. 44, no. 24, 22 November 2001 (2001-11-22), pages 4216 - 4224, XP002355780, ISSN: 0022-2623 *
MASQUELIER M ET AL: "AMINO ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN. 1. SYNTHESIS,PHYSICOCHEMICAL PROPERTIES, AND LYSOSOMAL DIGESTION", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 23, no. 11, 1980, pages 1166 - 1170, XP000914522, ISSN: 0022-2623 *
TAKEUCHI T ET AL: "Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 25 AUG 2000, vol. 275, no. 34, 25 August 2000 (2000-08-25), pages 26333 - 26342, XP002355779, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2447023A1 (en) 2002-11-28
EP1545572A2 (en) 2005-06-29
JP2005518332A (en) 2005-06-23
KR20040004642A (en) 2004-01-13
WO2002095007A3 (en) 2005-05-06
WO2002095007A2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
EP1545572A4 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
EP1463742A4 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
EP1296698A4 (en) Therapeutic agents - ii
GB0028429D0 (en) Therapy
GB0016787D0 (en) Compounds useful in therapy
AU7296801A (en) Il-17 molecules and uses thereof
EP1408978A4 (en) Novel phenylamino-pyrimidines and uses thereof
EP1453837A4 (en) Targeted therapeutics and uses thereof
AU9153601A (en) Portable sauna
IL154553A0 (en) Urocortin-iii and uses thereof
AU2002224553A1 (en) Human proteases
GB0124730D0 (en) Improvements in or relating to devices
AU2001236562A1 (en) Portable spa
GB0010871D0 (en) Opthalmic injector
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2003274402A1 (en) Fabric column and pad concrete form
EP1408985A4 (en) Novel pyridopyrimidones and uses thereof
GB0115780D0 (en) Therapeutic molecules and uses thereof
GB0102717D0 (en) Cells and uses therefor
EP1585971A4 (en) a-AMYLASE ASSAY AND USES THEREOF
AUPQ884500A0 (en) Novel therapeutic molecules and uses therefor - III
GB0128167D0 (en) Improvements in keyboards
AU2002304728A1 (en) Enzymes combination coadjuvating in the interferon therapy
AU2001272919A1 (en) Lp120 polypeptides and therapeutic uses thereof
AUPR453501A0 (en) Improvements in decals

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060915